Фибрилляция и трепетание предсердий. Клинические рекомендации 2025

Российское кардиологическое общество

При участии: Ассоциации сердечно-сосудистых хирургов России (АССХ), Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА)

Одобрено Научно-практическим Советом Минздрава Российской Федерации

1. Howick JH. The Philosophy of Evidence-based Medicine. Wiley.p.15. ISBN: 978-1-4443-4266-6.

2. Андреева Н. С., Реброва О. Ю., Зорин Н. А. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

3. Григорян С. В., Азарапетян Л. Г., Адамян К. Г. Миокардиальный фиброз и фибрилляция предсердий. Российский кардиологический журнал. 2018;(9):71-6.

4. Ланг Ф., Шальдах М. Развитие электрической турбулентности в предсердиях: электрофизиологические предпосылки. Progr. Вiomed. Res. 1999;4(1):42-8.

5. Митрофанова Л. Б., Ковальский Г. Б. Морфологические изменения миокарда при фибрилляции предсердий. Архив патологии. 2011;73(6):10-4.

6. Sanchez PL, Fernandez-Aviles F. Structural heart disease: a new chapter in cardiovascular disease. ESC Monographic issue: Structural Heart Disease. Eur Heart J. 2010;12:e1.

7. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422-34.

8. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423-34.

9. Wong CX, Sullivan T, Sun MT, et al. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation: A Meta-Analysis of 626 603 Individuals in 51 Studies. JACC: clinical electrophysiology. 2015;3:139-52.

10. Голухова Е. З., Громова О. И., Булаева Н. И. и др. Эпикардиальный жир и фибрилляция предсердий: роль профиброгенных медиаторов. Кардиология. 2018;58:58-64.

11. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659.

12. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. doi:10.1161/CIRCULATIONAHA.113.005119.

13. Colilla S, Crow A, Petkun W, et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U. S. Adult Population. Am J Cardiol. 2013;112(8):1142-7. doi:10.1016/j.amjcard.2013.05.063.

14. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart 2013;34(35):2746-51. doi:10.1093/eurheartj/eht280.

15. Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circulation Research. 2017;120(9):1501-17. doi:10.1161/CIRCRESAHA.117.309732.

16. Мареев Ю. В., Поляков Д. С., Виноградова Н. Г. и др. ЭПОХА: Эпидемиология фибрилляции предсердий в репрезентативной выборке Европейской части Российской Федерации. Кардиология. 2022;62(4):12-9. doi:10.18087/cardio.2022.4.n1997. EDN: NADMDK

17. Shkolnikova MA, Jdanov DA, Ildarova RA, et al. Atrial fibrillation among Russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a population-based study. J Geriatr Cardiol. 2020;17(2):74-84. doi:10.11909/j.issn.1671-5411.2020.02.002.

18. Al-Jazairi MIH, Nguyen BO, De With RR, et al. RACE 3 Investigators. Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. Europace. 2021;23(9):1359-68. doi:10.1093/europace/euab062.

19. Adiyaman A, Buist TJ, Beukema RJ, et al. Randomized Controlled Trial of Surgical Versus Catheter Ablation for Paroxysmal and Early Persistent Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2018;11(10):e006182. doi:10.1161/CIRCEP.118.006182.

20. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119:448.e1-19.

21. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigation altherapy. J Am Coll Cardiol. 2000;36:1303-9.

22. Sears SF, Serber ER, Alvarez LG, et al. Understanding atrial symptom reports: objective versus subjective predictors. Pacing Clin Electrophysiol. 2005;28:801-7.

23. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial fibrillation. Rev Esp Cardiol. 2010;63:1402-9.

24. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thromb Haemost. 2021;121(3):270-8. doi:10.1055/s-0040-1716408.

25. Schnabel RB, Pecen L, Rzayeva N, et al. Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe. J Am Heart Assoc. 2018;7(11):e007559. doi:10.1161/JAHA.117.007559.

26. Sandhu RK, Smigorowsky M, Lockwood E, et al. Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation. Can J Cardiol. 2017;33:450-5.

27. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation. 2015;131:2176-84.

28. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study. Circulation. 2017;136:1784-94.

29. Mairesse GH, Moran P, Van Gelder IC, et al. ESC Scientific Document Group. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017;19:1589-623.

30. Schnabel RB, Haeusler KG, Healey JS, et al. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN International Collaboration. Circulation. 2019;140:1834-50.

31. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631.

32. Yan BP, Lai WHS, Chan CKY, et al. Contact-Free Screening of Atrial Fibrillation by a Smartphone Using Facial Pulsatile Photoplethysmographic Signals. J Am Heart Assoc. 2018;7(8):e008585. doi:10.1161/JAHA.118.008585.

33. Jacobs MS, Kaasenbrood F, Postma MJ, et al. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018;20:12-8.

34. Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace. 2015;17(7):1023-9. doi:10.1093/europace/euv083.

35. Kaasenbrood F, Hollander M, Rutten FH, et al. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace. 2016;18:1514-20.

36. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111:1167-76.

37. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown. atrial fibrillation. A systematic review. Thromb Haemost. 2013;110:213-22.

38. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke. preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 2014;35:508-16.

39. Mahajan R, Perera T, Elliott A, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J. 2018;39:1407-15.

40. Boriani G, Glotzer TV, Ziegler PD, et al. Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden. Heart Rhythm. 2018;15:376-83.

41. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120-9.

42. Pastori D, Miyazawa K, Li Y, et al. Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. Clin Res Cardiol. 2020;109:96-102.

43. Gonzalez M, Keating RJ, Markowitz SM, et al. Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers. Heart Rhythm. 2014;11:2214-21.

44. Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий: клинические рекомендации. Москва: Министерство здравоохранения РФ, 2020. 185 с. EDN: BKDDMR

45. Donal E, Lip GY, Galderisi M, et al. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2016;17:355-83.

46. Мацкеплишвили С. Т., Саидова М. А., Мироненко М. Ю. и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271. doi:10.15829/1560-4071-2025-6271. EDN: TNLDFN

47. Sanna T, Diener HC, Passman RS, et al. CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478-86.

48. Yu S, Zhang H, Li H. Cardiac Computed Tomography Versus Transesophageal Echocardiography for the Detection of Left Atrial Appendage Thrombus: A Systemic Review and Meta‐Analysis. Journal of the American Heart Association. 2021;10:e022505. doi:10.1161/JAHA.121.022505.

49. Hunter RJ, Ginks M, Ang R, et al. Impact of variant pulmonary vein anatomy and image integration on long-term outcome after catheter ablation for atrial fibrillation. Europace. 2010;12(12):1691-7. doi:10.1093/europace/euq322.

50. Handbook of Cardiology in four volumes edited by Academician E. I. Chazov. Moscow, Praktika Publ., 2014. (In Russ.) Руководство по кардиологии в четырех томах под редакцией академика Е. И. Чазова. Москва, "Практика", 2014. ISBN: 978-5-89816-130-9.

51. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-9.

52. Hijazi Z, Oldgren J, Lindback J, et al. ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016; 387:2302-11.

53. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.

54. Granger CB, Alexander JH, McMurray JJ et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-92.

55. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.

56. O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258-64.

57. Antithrombotic therapy in cardiology. Edited by Panchenko E. P. M.: LLC "REMEDIUM GROUP", 2019. 256 p. (In Russ.) Антитромботическая терапия в кардиологии. Под ред. Панченко Е. П. М.: ООО "ГРУППА РЕМЕДИУМ", 2019. 256 с.: ил. ISBN: 978-5-906499-592.

58. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol. 2018;71:2162-75.

59. Lee SR, Lee HJ, Choi EK, et al. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. J Am Coll Cardiol. 2019;73:3295-308.

60. Wang CL, Wu VC, Kuo CF, et al. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study. Journal of the American Heart Association. 2018;7:e009263.

61. Rizos T, Guntner J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke. 2012;43:2689-94.

62. Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest Endosc. 2009;69:271-7.

63. Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med. 1998;339:153-9.

64. Choi JS, Choi JY, Cho HG, et al. Is esophagogastroduodenoscopy necessary in patients with positive fecal occult blood tests and negative colonoscopy? Scand J Gastroenterol. 2013;48:657-62. doi:10.3109/00365521.2013.792390.

65. Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin — associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost. 2014;111:14-8.

66. Nielsen PB, Larsen TB, Skjoth F, et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation. 2015;132:517-25.

67. Yung D, Kapral MK, Asllani E, et al. Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol. 2012;28:33-9.

68. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72.

69. Olesen JB, Lip GY, Hansen M. Letal Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

70. Zhu W, Xiong Q, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-VASc forpredicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation, Tex. Heart Inst. J. 2015;42:6-15.

71. Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9:39-48. doi:10.1111/j.1538-7836.2010.04085.x.

72. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500-10.

73. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.

74. Olesen JB, Lip GY, Hansen PR, et al. Bleeding risk in "real world" patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011;9:1460-7.

75. Roldan V, Marin F, Manzano-Fernandez S, et al The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2199-204.

76. Steg PG, Alam S, Chiang CE, et al. Realise AF investigators. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the Realise AF cross-sectional international registry. Heart. 2012;98:195-201.

77. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.

78. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.

79. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-6.

80. van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(6):1065-77. doi:10.1111/jth.13690.

81. Li YG, Miyazawa K, Wolff A, et al. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. Int J Cardiol. 2019;274:158-62. doi:10.1016/j.ijcard.2018.08.091.

82. Joundi RA, Cipriano LE, Sposato LA, Saposnik G. Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016;47:1364-7.

83. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225-32.

84. Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826-34.

85. Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-42.

86. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. Circulation. 2017;135:208-19. doi:10.1161/CIRCULATIONAHA.116.024057.

87. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY). 2020;12:24219-27.

88. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid. 2021;28(1):12-8. doi:10.1080/13506129.2020.1798922.

89. Vilches S, Fontana M, Gonzalez-Lopez E, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387-96. doi:10.1002/ejhf.2566.

90. Sjogren V, Grzymala-Lubanski B, Renlund H. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370-7.

91. Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality ofinternational normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-37.

92. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction ofadverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91.

93. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087-107.

94. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. PLoS One. 2017;12:e0188482. doi:10.1371/journal.pone.0188482.

95. Liu S, Li X, Shi Q, et al. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Curr Med Res Opin. 2018;34:415-21. doi:10.1080/03007995.2017.1384370.

96. Björck F, Renlund H, Lip GY, et al. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiol. 2016;1:172-80. doi:10.1001/jamacardio.2016.0199.

97. Tajer C, Ceresetto J, Bottaro FJ, et al. TERRA Trial investigators "Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina" Clinical Trial Clin Appl Thromb Hemost. 2017;23(5):445-53. doi:10.1177/1076029615623378.

98. Кропачева Е. С., Боровков Н. Н., Вавилова Т. В. и др. Быстрые темпы насыщения варфарином — предиктор развития чрезмерной гипокоагуляции. Модернизация алгоритма подбора дозы варфарина. Атеротромбоз. 2015;(1):74-86.

99. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-62.

100. Kim IS, Kim HJ, Kim TH, et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients withatrial fibrillation: A systematic review and meta-analysis. J Cardiol. 2018;72:105-12. doi:10.1016/j.jjcc.2018.01.015.

101. Kim IS, Kim HJ, Kim TH, et al. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. J Cardiol. 2018;72:284-91. doi:10.1016/j.jjcc.2018.03.009.

102. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous strokeor transient ischemic attack: An updated systematic review and meta-analysis ofrandomized controlled trials. Int J Stroke. 2017;12:589-96. doi:10.1177/1747493017700663.

103. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.

104. Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol. 2013;36:61-7. doi:10.1002/clc.22081.

105. Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.

106. Carmo J, Ferreira J, Costa F, et al. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials Int J Cardiol. 2017;244:196-201. doi:10.1016/j.ijcard.2017.06.004.

107. Friberg L, Rosenqvist M, Lip, G et al. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study. Circulation. 2012;125(19):2298-307. doi:10.1161/circulationaha.111.055079.

108. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace. 2014;16:631-8.

109. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. Br Med J. 1964;1:1209-12.

110. Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-14.

111. Perez-Gomez F, AlegriaE, Berjon J, et al. NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557-66.

112. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med. 1960;52:741-9.

113. Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-valve replacement. N Engl J Med. 1994;330:507-8; author reply 508-509.

114. Сhiang CW, Lo SK, Ko YS, et al. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med. 1998;128:885-9.

115. Atar S, Wishniak A, Shturman, A, et al. Fatal Association of Mechanical Valve Thrombosis With Dabigatran. Chest. 2013;144(1):327-8. doi:10.1378/chest.12-2486.

116. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395.

117. Pan KL, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835.

118. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017;69:1363-71.

119. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;209:181-3.

120. Cappato R, Ezekowitz MD, Klein AL, et al. X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346-55.

121. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-6.

122. Klein AL, Jasper SE, Katz WE, et al. ACUTE II Steering and Publications Committe for the ACUTE II Investigators. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transo-esophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J. 2006;27(23):2858-65. doi:10.1093/eurheartj/ehl353.

123. Stellbrink C, Nixdorff U, Hofmann T, et al. ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109(8):997-1003. doi:10.1161/01.CIR.0000120509.64740.DC.

124. Yigit Z, Küçükoglu MS, Okçün B, et al. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J. 2003;44(3):369-77. doi:10.1536/jhj.44.369.

125. Nuotio I, Hartikainen JE, Gronberg T, et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014;312:647-9.

126. Goette A, Merino JL, Ezekowitz MD, et all. ENSURE-AF investigators "Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSUREAF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. doi:10.1016/S0140-6736(16)31474-X.

127. Hansen ML, Jepsen RMHG, Olesen JB, et al. Thromboembolic risk in 16,274atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy. Europace. 2015;17:18-23.

128. Ezekowitz MD, Pollack CVJr, Halperin JL, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018; 39: 2959-71.

129. Kleemann T, Becker T, Strauss M, et al. Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation < 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocardiogr. 2009;22(12):1403-8. doi:10.1016/j.echo.2009.09.015.

130. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20.

131. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. doi:10.1093/europace/euab065.

132. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373-498.

133. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1973-80.

134. Henrik V, Peter BN, Søren PH, et al. Atrial Flutter and Thromboembolic Risk: A Systematic Review Heart. 2015;101(18):1446-55. doi:10.1136/heartjnl-2015-307550.

135. Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249-56. doi:10.1161/STROKEAHA.107.510321.

136. Tan S, Wang D, Liu M, et al. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol. 2014;261:905-12. doi:10.1007/s00415-014-7297-8.

137. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke. A Randomized Clinical Trial JAMA Neurol. 2017;74:1206-15. doi:10.1001/jamaneurol.2017.2161.

138. Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 2016;87:1856-62.

139. Macha K, Volbers B, Bobinger T, et al. Early Initiation of Anticoagulation withDirect Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. J Stroke Cerebrovasc Dis. 2016;25:2317-21. doi:10.1016/j.jstrokecerebrovasdis.2016.06.031.

140. Nguyen NY, Frishman WH. Restarting oral anticoagulation in patients with atrial fibrillation after an intracranial hemorrhage. Cardiol Rev. 2020;28:190-6.

141. Kurogi R, Nishimura K, Nakai M, et al.; J-ASPECT Study Collaborators. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology. 2018;90:e1143-9.

142. Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study. Stroke. 2015;46:2175-82.

143. Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non Vitamin-K Oral Anticoagulants (RAF-NOACs) study. J Am Heart Assoc. 2017;6(12):e007034. doi:10.1161/JAHA.117.007034.

144. Oldgren J, ∙ Åsberg S, ∙ Hijazi Z, ∙ et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study. Circulation. 2022;146:1056-66.

145. Fischer U, Koga M, Strbian D, et al. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 2023; 388:2411-21.

146. King BT, Lawrence PD, Milling TJ, et al. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. Int J Stroke. 2019;14:977-82.

147. Werring DJ, Dehbi HM, Ahmed N, et al. OPTIMAS investigators. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet. 2024: S0140-6736(24)02197-4.

148. Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ. 2014;4(2):e004425. doi:10.1136/bmjopen-2013-004425.

149. Кулеш А. А., Дёмин Д. А., Кучеренко С. С. 10 правил назначения пероральных антикоагулянтов после инсульта. Неврология, нейропсихиатрия, психосоматика. 2024;16(4):111-21.

150. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant reatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38:423-30.

151. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. doi:10.1093/eurheartj/ehad191.

152. Amsterdam EA, Wenger N, Brindis RG, et al. 2014 AHA/ACC Guidelines for the management of patients with non–ST-elevation acute coronary syndrome: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:e344-e426.

153. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med. 1983;309:396-403.

154. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.

155. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641-9.

156. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569-81.

157. Diener HC, Stanford S, Abdul-Rahim A, et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother. 2014;14:1019-28.

158. Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307:2600-8.

159. Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e99.

160. Giannandrea D, Caponi C, Mengoni A, et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry. 2019;90:619-23. doi:10.1136/jnnp-2018-318658.

161. Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385(9986):2465-76. doi:10.1016/S0140-6736(15)60292-6.

162. Liu M, Zheng Y, Li G. Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2018;27:2296-305.

163. Goldhoorn RB, van de Graaf RA, van Rees JM, et al. Endovascular Treatment for Acute Ischemic Stroke in Patients on Oral Anticoagulants: Results From the MR CLEAN Registry. Stroke. 2020;51:1781-9.

164. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European heart journal. 2016:50:e1-e88.

165. Diener HC, Eikelboom J. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11:225-231.

166. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298-304.

167. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634-40.

168. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-93.

169. Sindet-Pedersen C, Lamberts M, Staerk L, et al. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. J Am Coll Cardiol. 2018;72:1790-800. doi:10.1016/j.jacc.2018.07.054.

170. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronaryartery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129:1577-85. doi:10.1161/CIRCULATIONAHA.113.004834.

171. Woo D, Haverbusch M, Sekar P, et al. Effect of Untreated Hypertension on Hemorrhagic Stroke. Stroke. 2004;35:1703-8.

172. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967-73.

173. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30(6):1223-9.

174. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158(14):1513-21. doi:10.1001/archinte.158.14.1513.

175. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739‐49. doi:10.1160/TH11-05-0364.

176. Majeed A, Kim YK, Roberts RS, et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41:2860-6. doi:10.1161/STROKEAHA.110.593087.

177. Murthy SB, Gupta A, Merkler AE, et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage. Stroke. 2017;48(6):1594-600. doi:10.1161/strokeaha.116.016327.

178. Wilson D, Ambler G, Lee KJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol. 2019;18:653-65.

179. Joglar JA, Chung MK, Armbruster AL, et al; Peer Review Committee Members. 2023 ACC/ AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.

180. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61:2551-6.

181. Boersma LV, Schmidt B, Betts TR, et al., on behalf of the EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465-74.

182. Saw J, Fahmy P, Azzalini L, et al. Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure. J Cardiovasc Electrophysiol. 2017;28:39640.

183. Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of Direct Oral Anticoagulants for Hemorrhagic Transformation After Endovascular Treatment in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2022;31(7):106507.

184. Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141-7.

185. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.

186. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015;66(21):2271-81. doi:10.1016/j.jacc.2015.09.024.

187. Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, et al. Gastrointestinal Bleeding with Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018;11(5):e003998. doi:10.1161/CIRCOUTCOMES.117.003998.

188. Chan EW, Lau WC, Leung WK, et al. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology. 2015;149(3):586-95. doi:10.1053/j.gastro.2015.05.002.

189. Lee SR, Kwon S, Choi EK, et al. Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding. Cardiovasc Drugs Ther. 2022;36(4):679-89. doi:10.1007/s10557-021-07170-6.

190. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.

191. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation. 2012;125(2):375-80. doi:10.1161/CIRCULATIONAHA.111.019745.

192. Комаров А. Л., Шахматова О. О., Коробкова В. В. и др. Факторы риска и исходы желудочно-кишечных кровотечений у больных стабильной ишемической болезнью сердца: данные наблюдательного регистра длительной антитромботической терапии РЕГАТА-1. Российский кардиологический журнал. 2021;26(6):4465.

193. Biffi A, Anderson CD, Battey TW, et al. Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. JAMA. 2015;314(9):904-12. doi:10.1001/jama.2015.10082.

194. Vemulapalli S, Inohara T, Kim S, et al. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Am J Cardiol. 2019;123(10):1628-36. doi:10.1016/j.amjcard.2019.02.010.

195. Kärkkäinen JM, Miilunpohja S, Rantanen T, et al. Alcohol Abuse Increases Rebleeding Risk and Mortality in Patients with Non-variceal Upper Gastrointestinal Bleeding. Dig Dis Sci. 2015;60(12):3707-15. doi:10.1007/s10620-015-3806-6.

196. Askgaard G, Christensen AI, Nordestgaard B, et al. Alcohol and risk of non-traumatic bleeding events requiring hospital care in the general population: A prospective cohort study. Alcohol. 2020;87:73-8. doi:10.1016/j.alcohol.2020.04.009.

197. Dave M, Kumar A, Majmundar M, et al. Frequency, Trend, Predictors, and Impact of Gastrointestinal Bleeding in Atrial Fibrillation Hospitalizations. Am J Cardiol. 2021;146:29-35. doi:10.1016/j.amjcard.2021.01.020.

198. Palareti G, Cosmi B. Bleeding with anticoagulation therapy — who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102:268-78.

199. Tse G, Gong M, Li G, et al. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018;84:1868-82. doi:10.1111/bcp.13621.

200. Yang T, Zhou Y, Chen C, et al. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019;44:197-208. doi:10.1111/jcpt.12782.

201. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med. 2014;174:1330-8. doi:10.1001/jamainternmed.2014.236

202. Feldman DN, Wang TY, Chen AY, et al. In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry. J Am Heart Assoc. 2019;8:e011606. doi:10.1161/JAHA.118.011606.

203. Pollack CV. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2016;33:423-30. doi:10.1136/emermed-2015-204891.

204. Pollack CV Jr., Reilly PA, van Ryn J, et al. Еdarucizumab for dabigatran reversal — Full cohort analysis. N Engl J Med. 2017;377:431-41.

205. Гаглоева Д. А., Дзаурова Х. М., Зельберг М. А. и др. Предварительные результаты проспективного рандомизированного исследования по сравнению эффективности и безопасности рефралона и амиодарона при кардиоверсии у больных пароксизмальной формой фибрилляции и трепетания предсердий. Кардиоваскулярная терапия и профилактика. 2023;22(4):3527. doi:10.15829/1728-8800-2023-3527. EDN: EKXLTQ

206. Зельберг М. А., Миронов Н. Ю., Дзаурова Х. М. и др. Медикаментозная кардиоверсия кавутилидом (рефралоном) у пациентов с ранними рецидивами фибрилляции и трепетания предсердий после катетерной аблации легочных вен. Евразийский кардиологический журнал. 2024;(2):86-95. doi:10.38109/2225-1685-2024-2-86-95

207. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113(4):662-8. doi:10.1016/j.amjcard.2013.10.044.

208. Tapaskar N, Pang A, Werner DA, Sengupta N. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis. Dig Dis Sci. 2021;66(2):554-66. doi:10.1007/s10620-020-06248-9.

209. Кропачева Е. С., Землянская О. А., Кривошеева Е. Н., Панченко Е. П. Возобновление антикоагулянтной терапии и риск развития прогноз-определяющих событий у больных с фибрилляцией предсердий, перенесших большое кровотечение (по данным РЕГистра длительной Антитромботической ТерАпии — РЕГАТА-2). Терапевтический архив. 2022;94(12):1374-80.

210. Эрлих А. Д. Острый коронарный синдром без подъемов сегмента ST в практике российских стационаров: сравнительные данные регистров РЕКОРД-2 и РЕКОРД. Кардиология. 2012;(10):9-16.

211. Батурина О. А., Андреев Д. А., Ананичева Н. А. и др. Распространенность фибрилляции предсердий при остром коронарном синдроме и особенности назначения пероральных антитромботических препаратов. Кардиология. 2019;59(1):40-8. doi:10.18087/cardio.2019.1.10213

212. Бражник В.А, Минушкина Л. О., Эрлих А. Д. и др. Использование шкалы ОРАКУЛ для оценки геморрагического риска у пациентов с острым коронарным синдромом и фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):11-5.

213. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-24.

214. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169:472-8.

215. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-24.

216. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. doi:10.1016/S0140-6736(19)31872-0.

217. Lopes RD, Hong H, Harskamp RE, et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. JAMA Cardiol. 2019;4(8):747-55. doi:10.1001/jamacardio.2019.1880.

218. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21:192-3.

219. Fiedler KA, Maeng M, Mehilli J. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619-29. doi:10.1016/j.jacc.2015.02.050.

220. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-23. doi:10.1016/j.amjcard.2008.08.021.

221. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:11071115.

222. Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060-6.

223. Andreou I, Briasoulis A, Pappas C, et al. Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2018;32:287-94. doi:10.1007/s10557-018-6795-9.

224. Jackson LR II, Ju C, Zettler M, et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015;8:1880-9.

225. Casula, M, Fortuni, F, Ferlini M, et al. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Am J Cardiovasc Drugs. 2021;21:231-40. doi:10.1007/s40256-020-00436-8.

226. Ducrocq G, Wallace JS, Baron G, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European Heart J. 2010;31(10):1257-65.

227. Serruys PW, Onuma Y, Garg S, et al. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5(1):50-6. doi:10.4244/eijv5i1a9.

228. Сho MS, Kang DY, Ahn JM, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024;391(22):2075-86.

229. Lopes RD, Vora AN, Liaw D, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17-23. doi:10.1016/j.ahj.2018.03.001.

230. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13.

231. Helft G, Dambrin G, Zaman A, et al. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv. 2009;73(1):44-7. doi:10.1002/ccd.21758.

232. Borlich M, Zeymer U, Wienbergen H, et al. Impact of Access Site on Periprocedural Bleeding and Cerebral and Coronary Events in High-Bleeding-Risk Percutaneous Coronary Intervention: Findings from the RIVA-PCI Trial. Cardiol Ther. 2024;13(1):89-101. doi:10.1007/s40119-023-00343-48.

233. Kerneis M, Gibson CM, Chi G, et al. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. JACC Cardiovasc Interv. 2018;11(7):626-34. doi:10.1016/j.jcin.2017.11.009.

234. Nardin M, Verdoia M, Barbieri L, et al. Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta-Analysis of Randomized Trials. Curr Vasc Pharmacol. 2017;16:79-92.

235. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019;139(5):604-16. doi:10.1161/CIRCULATIONAHA.118.036768.

236. Lee SR, Rhee TM, Kang DY, et al. Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. Am J Cardiol. 2019;124(6):879-85. doi:10.1016/j.amjcard.2019.05.072.

237. Zhang H, Xue Z, Yi D, et al. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. Int Heart J. 2020;61(2):231-8. doi:10.1536/ihj.19-202.

238. Siega lD, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630-9.

239. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025 Erratum in: Chest. 2023;164(1):267. doi:10.1016/j.chest.2023.05.019.

240. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401. doi:10.1016/j.jacc.2011.03.031.

241. Douketis JD, Spyropoulos AC, Kaatz S, et al. BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373:823-33.

242. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084-93.

243. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014;129:2638-44.

244. Bajkin BV, Popovic SL, Selakovic SD. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. J Oral Maxillofac Surg. 2009;67:990-5.

245. Михайлов Е.Н., Лебедев Д. С., Гуреев С.В и др. Безопасность одновременного применения непрямых и прямых антикоагулянтов при катерной аблации фибрилляции предсердий: исследование на большой группе пациентов. Вестник аритмологии. 2008;(53):21-6.

246. Clark NP, Witt DM, Davies LE, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175:1163-8

247. Kirchhof P, Camm J, Goete A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383:1305-16. doi:10.1056/NEJMoa2019422.

248. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis. 2012;105:226-38. doi:10.1016/j.acvd.2011.11.005.

249. Chen SJ, Yin YH, Dong Y, et al. Efficacy of rate and rhythm control strategy in patients with atrial fibrillation: meta-analysis. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:68-72.

250. Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability (ESC). European Heart Journal. 2019;40:1257-64.

251. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014; 160:760-73.

252. Chatterjee S, Sardar P, Lichstein E, et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE. 2013;36:122-33.

253. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J. 2009;85:303-12.

254. Kim H, Kim TH, Cha MJ, et al. A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prеvention of Atrial Fibrillation (CODE-AF) Registry. Korean Circ J. 2017;47:877-87. doi:10.4070/kcj.2017.0146.

255. Jafri SH, Xu J, Warsi I, Cerecedo-Lopez CD. Diltiazem versus metoprolol for the management of atrial fibrillation: A systematic review and meta-analysis. Am J Emerg Med. 2021;48:323-7. doi:10.1016/j.ajem.2021.06.053.

256. Hargrove KL, Robinson EE, Lusk KA, et al. Comparison of sustained rate control in atrial fibrillation with rapid ventricular rate: Metoprolol vs. Diltiazem. Am J Emerg Med. 2021;40:15-9. doi:10.1016/j.ajem.2020.11.073.

257. Blackshear JL, Stambler BS, Strauss WE, et al. Control of heart rate during transition from intravenous to oral diltiazem in atrial fibrillation or flutter. Am J Cardiol. 1996;78(11):1246-50. doi:10.1016/s0002-9149(96)00604-2.

258. Means KN, Gentry AE, Nguyen TT. Intravenous Continuous Infusion vs. Oral Immediate-release Diltiazem for Acute Heart Rate Control. West J Emerg Med. 2018;19(2):417-22. doi:10.5811/westjem.2017.10.33832.

259. de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165:258-62.

260. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-73.

261. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-10.

262. Groenveld HF, Tijssen JG, Crijns HJ, et al. RACE II Investigators. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol. 2013;61:741-8. doi:10.1016/j.jacc.2012.11.038.

263. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.

264. Allen LA, Fonarow GC, Simon DN, et al. ORBIT‐AF Investigators. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691-8.

265. Yu HT, Yang PS, Lee H, et al. Outcomes of Rate-Control Treatment in Patients With Atrial Fibrillation and Heart Failure — A Nationwide Cohort Study. Circ J. 2018;82:652-8. doi:10.1253/circj.CJ-17-0669.

266. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489-97.

267. Andrey JL, Romero S, Garcia-Egido A et al. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. Int J Clin Pract. 2011;65:1250-8.

268. Kotecha D, Bunting KV, Gill SK, et al. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020;324(24):2497-508.

269. Nergardh AK, Rosenqvist M, Nordlander R, et al. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebocontrolled study. Eur Heart J. 2007;28:1351-7.

270. Zehender M, Hohnloser S, Muller B, et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992;19:1054-9.

271. Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28:446-50.

272. Crijns HJ, Weijs B, Fairley AM, et al. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. Int J Cardiol. 2014;172:588-94.

273. Coll-Vinent B, Sala X, Fernandez C, et al. Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med. 2003;42:767-72.

274. Del Arco C, Martin A, Laguna P, et al. Analysis of current management of atrial fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med. 2005;46:424-30.

275. Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency department management and 1-year outcomes of patients with atrial flutter. AnnEmergMed. 2011;57:564-71.

276. Aronow WS. Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review. 2008;16(5):230-9. doi:10.1097/crd.0b013e3181723694.

277. Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol. 2003;91:489-91.

278. Olasveengen TM, de Caen AR, Mancini ME, et al. ILCOR Collaborators. 2017 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations summary. Circulation. 2017;136:e424e440.

279. Morris JJ Jr, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation: immediate and long-term results and selection of patients. Ann Intern Med. 1966;65:216-31.

280. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380:238-46.

281. Pluymaekers N, Dudik E, Luermans J, et al. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019;380(16):1499-508. doi:10.1056/NEJMoa1900353.

282. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-72.

283. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anteriorlateral electrode positions for external cardioversion of atrial fibrillation: a randomized trial. Lancet. 2002;360:1275-19.

284. Kirchhof P, Monnig G, Wasmer K, et al. A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J. 2005;26:1292-7.

285. Goldner BG, Baker J, Accordino A, et al. Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment. Am Heart J. 1998;136:961-4.

286. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241-7.

287. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351:2384-91.

288. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542-7.

289. Saborido CM, Hockenhull J, Bagust A, et al. Systematic review and cost-effectiveness evaluation of "pill-in-the-pocket" strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess. 2010;14:iii-iv,1-75.

290. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003;87:121-8. doi:10.1016/S0167-5273(02)00467-9.

291. Kirchhof P, Josephson ME. Clinical cardiac electrophysiology. Techniques and interpretation. Philadelphia, PA: Lippincott Williams and Wilkins, 2008. pp: 285-339; 339-446.

292. Manios EG, Mavrakis HE, Kanoupakis EM, et al. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther. 2003;17:31-3.

293. Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. JACC. 1996;28:700-70.

294. Singh SN, Tang XC, Reda D, et al. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152-5.

295. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53.

296. Sandau KE, Funk M, Auerbach A, et al; American Heart Association Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Cardiovascular Disease in the Young. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation. 2017;136(19):e273e344. doi:10.1161/CIR.000000000000527.

297. Tisdale JE, Chung MK, Campbell KB, et al.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905.

298. Zhang N, Guo JH, Zhang H, et al. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract. 2005;59:1395-400.

299. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950-3.

300. Halpern SW, Ellroot G, Singh BN, et al. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J. 1980;44:589-95.

301. Fenster PE, Comess KA, Marsh A, et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501-4.

302. Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther. 1998;12:75-81

303. Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99:1721-5.

304. Stiell IG, Sivilotti MLA, Taljaard M, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. Lancet. 2020;395(10221):339-49. doi:10.1016/S0140-6736(19)32994-0.

305. Stiell IG, Clement CM, Symington C, et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med. 2007;14:1158-64.

306. Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC. 2003;41:255-62.

307. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538-45.

308. Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265-73.

309. Юричева Ю. А., Соколов С. Ф., Голицын С. П. и др. Новый антиаритмический препарат III класса ниферидил как эффективное средство восстановления синусового ритма при персистирующей форме мерцательной аритмии. Вестник аритмологии. 2012;(70):32-43.

310. Миронов Н. Ю., Влодзяновский В. В., Юричева Ю. А. и др. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):664-9. doi:10.20996/1819-6446-2018-14-5-664-669.

311. Миронов Н. Ю., Влодзяновский В. В., Юричева Ю. А. и др. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 2: оценка безопасности. Рациональная фармакотерапия в кардиологии. 2018;14(6):826-30. doi:10.20996/1819-6446-2018-14-6-826-830.

312. Дзаурова Х. М., Миронов Н. Ю., Юричева Ю. А. и др. Эффективность и безопасность применения модифицированного протокола введения отечественного антиаритмического препарата III класса для купирования пароксизмальной формы фибрилляции предсердий. Терапевтический архив. 2021;93(9):1052-7. doi:10.26442/00403660.2021.09.201008.

313. Миронов Н. Ю., Юричева Ю. А., Влодзяновский В. В. и др. Опыт клинического применения отечественного антиаритмического препарата III класса для медикаментозной кардиоверсии фибрилляции и трепетания предсердий: результаты многоцентрового исследования. Часть 1: методология исследования и оценка эффективности. Рациональная фармакотерапия в кардиологии. 2021;17(2):193-9. doi:10.20996/1819-6446-2021-03-05.

314. Миронов Н.Ю., Юричева Ю.А., Влодзяновский В.В. и др. Опыт клинического применения отечественного антиаритмического препарата III класса для медикаментозной кардиоверсии фибрилляции и трепетания предсердий: результаты многоцентрового исследования. Часть 2: оценка безопасности лечения. Рациональная фармакотерапия в кардиологии. 2021;17(5):668-73.

315. Гаглоева Д. А., Миронов Н. Ю., Дзаурова Х. М. и др. Результаты проспективного рандомизированного исследования по сравнению эффективности и безопасности применения рефралона и амиодарона для восстановления синусового ритма у больных пароксизмальной формой фибрилляции и трепетания предсердий. Вестник аритмологии. 2024;31(1):63-70. doi:10.35336/VA-1289.

316. Гаглоева Д. А., Дзаурова Х. М., Зельберг М. А. и др. Эффективность и безопасность раннего назначения противорецидивной антиаритмической терапии у пациентов с фибрилляцией и трепетанием предсердий после медикаментозной кардиоверсии рефралоном. Кардиология. 2023;63(6):21-7. doi:10.18087/cardio.2023.6.n2276.

317. Олесин А. И., Смолин З. Ю., Коновалова О. А. и др. Оценка эффективности чреспищеводной электрокардиостимуляции для купирования впервые выявленного трепетания предсердий 1-го типа у больных ишемической болезнью сердца. Терапевтический архив. 2009;(9):37-41.

318. Зинченко Ю. В. Влияние частоты предсердных волн на эффективность чреспищеводной электрокардиостимуляции у больных с изолированным трепетанием предсердий. Украинский кардиологический журнал. 2010;(2):61-7.

319. Сулимов В. А., Дубровский И. А., Канорский С. Г. и др. Чреспищеводная электрическая стимуляция сердца. М.: 2015. 216 с. ISBN: 978-5-9704-3209-9.

320. Jacob I, Haft MD, Bernard D, Kosowsky MD, et al. Termination of atrial flutter by rapid electrical pacing of the atrium. J Am Coll Cardiol. 1967;20:239-44.

321. Gerd Fröhlig, Semi Sen, Gerd Rettig et al. Termination of atrial flutter during DDD pacing by rapid overdrive stimulation using the implanted pacemaker lead system. J Am Coll Cardiol. 1986;57:483-5. doi:10.1016/0002-9149(86)90781-2.

322. Peters RW, Weiss DN, Carliner NH, et al. Overdrive pacing for atrial flutter. Am J Cardiol. 1994;74:1021-3.

323. Peters RW, Shorofsky SR, Pelini M, et al. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999;137:100.

324. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-183.

325. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.

326. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-20.

327. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77.

328. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009;30:2969-77.

329. Wilber DJ, Pappone C, Neuzil P, et al. ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303:333-40.

330. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049.

331. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-31.

332. Параскевова Д. П., Минаев А. В., Степанова Н. М., Астафьева Т. А. Тактика антиаритмической терапии у пациентов при выполнении сочетанной хирургической коррекции врожденного порока сердца и нарушений ритма. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2023;24(S3):168. EDN: FLIBXO.

333. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65:2159-69.

334. Westcott SK, Beach LY, Matsushita F, et al. Relationship Between Psychosocial Stressors and Atrial Fibrillation in Women >45 Years of Age. Am J Cardiol 2018;122(10):1684-87.

335. Mont L, Sambola A, Brugada J, et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J. 2002;23:477-82.

336. Krijthe BP, Heeringa J, Kors JA, et al. Serum Potassium Levels and the Risk of Atrial Fibrillation: The Rotterdam Study. Int J Cardiol. 2013:168(6):5411-5.

337. Kodama S, Saito K, Tanaka S, et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2011;57:427-36.

338. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcome sin patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014;114:1217-22.

339. Chang S-H, Wu L-S, Chiou M-J, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohortand in vitro studies. Cardiovasc Diabetol. 2014;13:123.

340. Vizzardi E, Sciatti E, Bonadei I, et al. Obstructive sleep apnoea-hypopnoea and arrhythmias: new updates. J Cardiovasc Med. (Hagerstown). 2017;18:490-500.

341. Frost L, Vestergaard P, Mose-kilde L. Hyperthyroidism and risk of atrial fibrillation or flutter. a population-based study. Arch Intern Med. 2004;164:1675-8.

342. Kim EJ, Lyass A, Wang N, et al. Relation of hypothy-roidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J. 2014;167:123-6.

343. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2014;7:620-5.

344. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-12.

345. Gao X, Guha A, Buck B, et al. Initiation and outcomes with Class Ic antiarrhythmic drug therapy. Indian Pacing Electrophysiol J. 2018;18(2):68-72. doi:10.1016/j.ipej.2017.12.001.

346. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 2000;47:219-33.

347. Kääb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J. 2003;24:649-57.

348. Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol. 2010;106:263-8.

349. Choy AM, Darbar D, Dell’Orto S et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396-401.

350. Kirchhof P, Franz MR, Bardai A, et al. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol. 2009;54:143-9.

351. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201-8.

352. Valembois L, Audureau E, Takeda A, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049.

353. Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88:640-5.

354. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418-23.

355. Dogan A, Ergene O, Nazli C, et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol. 2004;59:255-61.

356. Pritchett EL, Page RL, Carlson M, et al. Efficacy and safety of sustained release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003;92:941-6.

357. Kurbanov RD, Abdullaev TA. Pharmacodynamics and efficacy of allapinine in patients with cardiac arrhythmias. Clinical medicine. 1988;(10):52-5. (In Russ.) Курбанов Р. Д., Абдуллаев Т. А. Фармакодинамика и эффективность аллапинина у больных с нарушениями ритма сердца. Клиническая медицина. 1988;(10):52-5.

358. Kokina B, Strēlnieks A, Pupkeviča I, et al. Sinus rhythm maintenance after electrical cardioversion for atrial fibrillation in high-risk patients — comparative efficacy of antiarrhythmic medications. Proceedings of the Latvian academy of sciences. 2021;75(1): 32-9. doi:10.2478/prolas-2021-0006.

359. Voronin AV, Blagova OV. Etatsizin: a place in the treatment of arrhythmias. Cardiology and cardiovascular surgery. 2009;(4):62-8. (In Russ.) Недоступ А. В., Благова О. В. Этацизин: место в лечении аритмий. Кардиология и сердечно-сосудистая хирургия. 2009;(4):62-8.

360. Батушкин В. В., Науменко Е. В. Эффективная фармакологическая поддержка синусового ритма у больных с персистирующей формой фибрилляции предсердий. Укр. кардіол. журн. 2005;2:65-70.

361. Лозинский Л. Г., Замотаев И. П., Керимова Р. Э. и др. Результаты лечения пароксизмальной мерцательной аритмии этацизином®. Кардиология. 1989;(7):37-40.

362. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med.1991;324:781-8.

363. Соколов С. Ф. Результаты клинического изучения препарата аллапинин и современные подходы к лечению больных с нарушениями ритма сердца. Вестник аритмологии. 2011;64:60-70.

364. Соколов С. Ф., Бомонина Е. В. Сравнительная эффективность и безопасность аллапинина, этацизина и амиодарона и выбор оптимальной антиаритмической терапии по контролю ритма при пароксизмальной мерцательной аритмии. Кардиология: новости, мнения, обучение. 2015;3(6):65-75.

365. Allen LaPointe NM, Dai D, et al. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. Am J Cardiol. 2015;115(3):316-22. doi:10.1016/j.amjcard.2014.11.005.

366. Gulizia M, Mangiameli S, Orazi S, et al. PITAGORA Study Investigators. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J. 2008;155(1):100-7. doi:10.1016/j.ahj.2007.08.033.

367. Рахманова М. М., Соколов С. Ф. Эффективность аллапинина в сравнении с хинидина бисульфатом в предупреждении рецидивов персистирующей фибрилляции предсердий после восстановления синусового ритма. Кардиология. 2014;54(9):33-8.

368. Ревишвили А. Ш., Голицын С. П., Аксентьев С. Б. и др. Сравнительное исследование лаппаконитина гидробромида пролонгированного и пропафенона у пациентов с пароксизмальной фибрилляцией предсердий. Врач. 2024;35(1):20-6.

369. Кейко О. И., Регушевская Д. В., Благова О. В. и др. Возможности применения этацизина в лечении пациентов с фибрилляцией предсердий. Кардиология и сердечно-сосудистая хирургия. 2011;4(6):53-6.

370. Подзолков В. И., Тарзиманова А. И., Моххамади Л. Н. Прогрессирование фибрилляции предсердий у больных артериальной гипертензией при выборе различной тактики лечения аритмии. Кардиология. 2017;57(11):29-33. doi:10087/cardio.2017.11.10051.

371. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385-94.

372. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d, l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d, l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270-7.

373. Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329-45.

374. Goldschlager N, Epstein AE, Naccarelli GV, et al. Practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-9.

375. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009;16:43-8.

376. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic. Survival ventricular arrhythmia Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77=82.

377. AFFIRM study investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20=9.

378. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pretreatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J. 2004;25:144=50.

379. Galperin J, Elizari MV, Chiale PA, et al. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6:341-50.

380. Сычев О. С., Романова Е. Н., Срибная О. В. Результаты клинического исследования "оценка эффективности и безопасности препарата этацизина у больных с нарушениями ритма без выраженной органической патологии сердца". Аритмологія. 2016;3(19):3-10.

381. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357-64.

382. Cosedis NJ, Johannessen A, Raatikainen P, et al. Radiofrequency ablationas initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587-95.

383. Arbelo E, Brugada J, Hindricks G, et al. Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J. 2014;35:1466-78.

384. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2:349-61.

385. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-8.

386. Leung LWM, Akhtar Z, Seshasai SRK, Gallagher MM. First-line management of paroxysmal atrial fibrillation: is it time for a ‘pill in the bin’ approach? A discussion on the STOP AF First, EARLY AF, Cryo-FIRST, and EAST-AF NET 4 clinical trials. Europace. 2022;24(4):533-7. doi:10.1093/europace/euab259.

387. Kuck KH, Albenque JP, Chun KJ, et al.; FIRE AND ICE Investigators. Repeat Ablation for Atrial Fibrillation Recurrence Post Cryoballoon or Radiofrequency Ablation in the FIRE AND ICE Trial. Circ Arrhythm Electrophysiol. 2019;12(6):e007247. doi:10.1161/CIRCEP.119.007247.

388. Hermida JS, Chen J, Meyer C, et al. Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study. Am Heart J. 2020;222:64-72. doi:10.1016/j.ahj.2019.12.006.

389. Lemoine MD, Obergassel J, Jaeckle S, et al. Pulsed-fieldvs. cryoballoon-based pulmonary vein isolation: lessons from repeat procedures. Europace. 2024;26(9):euae221. doi:10.1093/europace/euae221.

390. Della Rocca DG, Marcon L, Magnocavallo M, et al. Pulsed electric field, cryoballoon, and radiofrequency for paroxysmal atrial fibrillation ablation: a propensity score-matched comparison. Europace. 2023;26(1):euae016. doi:10.1093/europace/euae016.

391. Jia K, Jin Q, Liu A, Wu L. Remote magnetic navigation versus manual control navigation for atrial fibrillation ablation: A systematic review and meta-analysis. J Electrocardiol. 2019;55:78-86. doi:10.1016/j.jelectrocard.2019.05.001.

392. Song W, Lv T, Zhang N, et al. Long‐term efficacy and safety of cryoballoon ablation of atrial fibrillation: a systematic review and meta‐analysis. Pacing and Clinical Electrophysiology. 2024;47(1):49-57.

393. Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring: A Randomized Clinical Trial. Circulation. 2019;140(22):1779-88. doi:10.1161/CIRCULATIONAHA.119.042622.

394. Andrade JG, Deyell MW, Khairy P, et al. Atrial fibrillation progression after cryoablation vs. radiofrequency ablation: the CIRCA-DOSE trial. Eur Heart J. 2024;45(7):510-8. doi:10.1093/eurheartj/ehad572.

395. Shurrab M, Di Biase L, Briceno DF, et al. Impact of Contact Force Technology on Atrial Fibrillation Ablation: A Meta-Analysis. J Am Heart Assoc. 2015;4(9):e002476. doi:10.1161/JAHA.115.002476.

396. Virk SA, Ariyaratnam J, Bennett RG, Kumar S. Updated systematic review and meta-analysis of the impact of contact force sensing on the safety and efficacy of atrial fibrillation ablation: discrepancy between observational studies and randomized control trial data. Europace. 2019;21(2):239-49. doi:10.1093/europace/euy266.

397. Osorio J, Hussein AA, Delaughter MC, et al. Very High-Power Short-Duration, Temperature-Controlled Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: The Prospective Multicenter Q-FFICIENCY Trial. JACC Clin Electrophysiol. 2023;9(4):468-80. doi:10.1016/j.jacep.2022.10.019.

398. Ariyarathna N, Kumar S, Thomas SP, et al. Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias: Evolution or History Repeating Itself? JACC Clin Electrophysiol. 2018;4(6):707-23. doi:10.1016/j.jacep.2018.03.014.

399. Anselmino M, Matta M, D’Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:1011-8.

400. Ganesan AN, Nandal S, Luker J, et al. Catheter ablation of atrial fibrillation inpatients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ. 2015;24:270-80.

401. Al Halabi S, Qintar M, Hussein A, et al. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol. 2015;1:200-9.

402. Di Biase L, Mohanty P, Mohanty S, et al. Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;134:e1989-90. doi:10.1161/CIRCULATIONAHA.115.019406.

403. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAFtrial). Circ Arrhythm Electrophysiol. 2014;7:31-8.

404. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequencyablation for persistent atrial fibrillation in patients with advanced heart failure andsevere left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97:740-7.

405. Marrouche NF, Brachmann J, Andresen D, et al., for the CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 2018;378:417-27. doi:10.1056/NEJMoa1707855.

406. Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST) Europace, 2021;23(3):362-9. doi:10.1093/europace/euaa298.

407. Chen YW, Bai R, Lin T, et al. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome? Pacing Clin Electrophysiol. 2014;37:403-11.

408. Khaykin Y, Marrouche NF, Martin DO, et al. Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol. 2004;15:784-9.

409. Zhang XD, Gu J, Jiang WF, et al. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J. 2014;35:1327-34. doi:10.1093/eurheartj/ehu017.

410. Zhou L, He L, Wang W, et al. Effect of repeat catheter ablation vs. antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fibrillation after atrial fibrillation catheter ablation: data from CHINA-AF registry. Europace 2023;25:382-9. doi:10.1093/europace/euac169.

411. Fink T, Metzner A, Willems S, et al. Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the German ablation registry. Clin Res Cardiol 2019;108:1354-63. doi:10.1007/s00392-019-01471-5.

412. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009;104:671-7.

413. Schmieder S, Ndrepepa G, Dong J, et al. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J. 2003;24:956-62.

414. Bandini A, Golia P, Caroli E, et al. Atrial fibrillation after typical atrial flutter ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown). 2011;12:110-5.

415. Van Gelder IC, Rienstra M, Bunting KV, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45(36):3314-414 doi:10.1093/eurheartj/ehae176.

416. Wang TKM, Liao YB, Wang MTM, Martin A. Catheter vs thoracoscopic ablation for atrial fibrillation: Meta-analysis of randomized trials. J Arrhythm. 2020;36(4):789-93 doi:10.1002/joa3.1239.

417. Rattanawong P, Kanitsoraphan C, Kewcharoen J, et al. Surgical versus catheter ablation in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol. 2022;33(10):2152-63. doi:10.1111/jce.15617.

418. van der Heijden CAJ, Vroomen M, Luermans JG, et al. Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2019;56:433-43. doi:10.1093/ejcts/ezy475.

419. Aerts L, Kawczynski MJ, Bidar E, et al. Short- and long-term outcomes in isolated vs. hybrid thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis. Europace. 2024;26(10):euae232. doi:10.1093/europace/euae232.

420. Boersma LV, Castella M, van Boven W, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation. 2012;125:23-30.

421. Castella M, Kotecha D, van Laar C, et al. Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial. Europace. 2019;21:746-53. doi:10.1093/europace/euy325.

422. Blomstrom-Lundqvist C, Johansson B, Berglin E, et al. A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation inpatients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J. 2007;28:2902-8.

423. Doll N, Weimar T, Kosior DA, et al. Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial. EClinicalMedicine. 2023;61:102052. doi:10.1016/j.eclinm.2023.102052.

424. Ревишвили А. Ш., Стребкова Е. Д., Артюхина Е. А. и др. Эффективность торакоскопического лечения непароксизмальных форм фибрилляции предсердий. Вестник аритмологии. 2023;30(3):23-31. doi:10.35336/VA-1160.

425. Varzaly JA, Lau DH, Chapman D, et al. Hybrid ablation for atrial fibrillation: A systematic review and meta-analysis. JTCVS Open. 2021;7:141-54. doi:10.1016/j.xjon.2021.07.005.

426. van der Heijden CAJ, Weberndörfer V, Vroomen M, et al. Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: a randomized controlled trial. JACC Clin Electrophysiol. 2023;9:1013-23. doi:10.1016/j.jacep.2022.12.011.

427. Стребкова Е. Д., Ревишвили А. Ш., Малышенко Е. С. и др. Отдаленные результаты торакоскопического лечения фибрилляции предсердий. Вестник аритмологии. 2023;30(2):59-69. doi:10.35336/VA-2023-2-08.

428. Таймасова И. А., Артюхина Е. А., Ревишвили А. Ш. Сравнительный анализ отдаленных результатов торакоскопической и катетерной аблации с использованием индекса аблации у пациентов с непароксизмальными формами фибрилляции предсердий. Вестник аритмологии. 2023;30(2):11-9. doi:10.35336/VA-2023-2-02.

429. Weimar T, Schena S, Bailey MS, et al. The cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ Arrhythm Electrophysiol. 2012;5:8-14

430. Lawrance CP, Henn MC, Miller JR, et al. A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay. J Thorac Cardiovasc Surg. 2014;148:955-61; discussion 962-952.

431. Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the Cox Maze III procedure to aortic valve replacement and coronary artery bypasssurgery? J Thorac Cardiovasc Surg. 2012;143:936-44.

432. Gillinov AM, Gelijns AC, Parides MK, et al. CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015;372:1399-409

433. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013;1:Cd003611.

434. Ревишвили А. Ш., Кадырова М., Стребкова Е. Д. и др. Ампутация ушка левого предсердия с использованием эндостеплера при торакоскопической аблации фибрилляции предсердий. Комплексные проблемы сердечно-сосудистых заболеваний. 2023;12(1):58-71. doi:10.17802/2306-1278-2023-12-1-58-71.

435. McClure GR, Belley-Cote EP, Jaffer IH, et al. Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace. 2018;20:1442-50. doi:10.1093/europace/eux336.

436. Gao Y, Luo H, Yang R, et al. Safety and efficacy of Cox-Maze procedure for atrial fibrillation during mitral valve surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Surg. 2024;19(1):140. doi:10.1186/s13019-024-02622-0.

437. Gemelli M, Gallo M, Addonizio M, et al. Surgical Ablation for Atrial Fibrillation During Mitral Valve Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2023;209:104-13. doi:10.1016/j.amjcard.2023.09.088.

438. Sef D, Trkulja V, Raja SG, et al. Comparing mid-term outcomes of Cox-Maze procedure and pulmonary vein isolation for atrial fibrillation after concomitant mitral valve surgery: A systematic review. J Card Surg. 2022;37(11):3801-10. doi:10.1111/jocs.16888.

439. Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart. 2014;100:722-30. doi:10.1136/heartjnl-2013-305351.

440. Huffman MD, Karmali KN, Berendsen MA, et al. Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. Cochrane Database Syst Rev. 2016;8:CD011814. doi:10.1002/14651858.CD011814.

441. Ревишвили А. Ш., Попов В. А., Аминов В. В. и др. Влияет ли применение криоаблации на результаты операции "Лабиринт IV" при коррекции пороков митрального клапана? Грудная и сердечно-сосудистая хирургия. 2024;(6):817-28. doi:10.24022/0236-2791-2024-66-6-817-828.

442. Ревишвили А. Ш., Попов В. А., Аминов В. В. и др. Влияет ли операция "Лабиринт" на результаты протезирования митрального клапана в госпитальном периоде? Вестник аритмологии. 2019;26(2):37-44. doi:10.35336/VA-2019-2-37-44.

443. Cheng DC, Ad N, Martin J, et al. Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations (Phila). 2010;5:84-96.

444. Suwalski P, Kowalewski M, Jasiński M, et al. Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery. Eur J Cardiothorac Surg. 2020;57(4):691-700. doi:10.1093/ejcts/ezz298.

445. Treffalls JA, Hogan KJ, Brlecic PE, et al. Influence of concomitant ablation of nonparoxysmal atrial fibrillation during coronary artery bypass grafting on mortality and readmissions. JTCVS Open. 2023;16:355-69. doi:10.1016/j.xjon.2023.09.043.

446. Mehaffey JH, Hayanga JWA, Wei LM, et al. Concomitant Treatment of Atrial Fibrillation in Isolated Coronary Artery Bypass Grafting. Ann Thorac Surg. 2024;117(5):942-9. doi:10.1016/j.athoracsur.2023.11.034.

447. Vroomen M, Franke U, Senges J, et al. Outcomes of surgical ablation for atrial fibrillation in on-versus off-pump coronary artery bypass grafting. Interdiscip Cardiovasc Thorac Surg. 2024;39(3):ivae139. doi:10.1093/icvts/ivae139.

448. Ревишвили А. Ш., Попов В. А., Малышенко Е. С. и др. Предикторы рецидива фибрилляции предсердий после симультанной операции "Лабиринт V" и коронарного шунтирования. Вестник аритмологии. 2024;31(1): 28-38. doi:10.35336/VA-1246.

449. Ревишвили А. Ш., Попов В. А., Малышенко Е. С. и др. Оправданна ли операция "Лабиринт V" при пароксизмальной форме фибрилляции предсердий в сочетании с коронарным шунтированием? Грудная и сердечно-сосудистая хирургия. 2024;(4):493-507. doi:10.24022/0236-2791-2024-66-4-493-507.

450. Ревишвили А. Ш., Попов В. А., Аминов В.В. и др. Хирургическое лечение пароксизмальных форм фибрилляции предсердий при коронарном шунтировании: изоляция устьев легочных вен в сравнении с операцией "Лабиринт V". Комплексные проблемы сердечно-сосудистых заболеваний. 2022;11(4):47-61.

451. Ревишвили А. Ш., Попов В. А., Малышенко Е. С. и др. Операции Лабиринт V для симультанного хирургического лечения фибрилляции предсердий при коронарном шунтировании. Минимально инвазивная сердечно-сосудистая хирургия. 2022;1(1):43-55.

452. Ревишвили А. Ш., Попов В. А., Плотников Г. П. и др. Сравнительная оценка эффективности радиочастотной изоляции устьев легочных в сочетании с медикаментозной терапией амиодароном для профилактики фибрилляции предсердий после аортокоронарного шунтирования. Вестник аритмологии. 2019;26(3):29-36. doi:10.35336/VA-2019-3-29-36.

453. Visanji M, Belley-Côté EP, Pandey A, et al. Prophylactic ablation during cardiac surgery in patients without atrial fibrillation: a systematic review and meta-analysis of randomized trials. Interdiscip Cardiovasc Thorac Surg. 2024;39(6):ivae195. doi:10.1093/icvts/ivae195.

454. Dąbrowski EJ, Kurasz A, Pasierski M, et al; Thoracic Research Centre. Surgical Coronary Revascularization in Patients With Underlying Atrial Fibrillation: State-of-the-Art Review. Mayo Clin Proc. 2024;99(6):955-70. doi:10.1016/j.mayocp.2023.12.005.

455. Willekes CL, Fanning JS, Heiser JC, et al. Randomized feasibility trial of prophylactic radiofrequency ablation to prevent atrial fibrillation after cardiac surgery. J Thorac Cardiovasc Surg. 2024;167(6):2129-35. doi:10.1016/j.jtcvs.2023.03.010.

456. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720-9.

457. Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events — European Registry in Atrial Fibrillation (PREFER in AF) BMJ Open 2019;9:e022478. doi:10.1136/bmjopen-2018-022478.

458. Zhu J, Wang C, Gao D, et al. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J. 2012;42:1078-87.

459. Gillinov AM, Bagiella E, Moskowitz AJ, et al. CTSN. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. N Engl J Med. 2016;374:1911-21.

460. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150:288-93.

461. Tsai YC, Phan K, Munkholm-Larsen S, et al. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J Cardiothorac Surg. 2015;47:847-54.

462. Weerasooriya R, Davis M, Powell A, et al. The Australian intervention randomized control of rate in atrialfi brillation trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1697-702.

463. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101:1138-44.

464. Gasparini M, Auricchio A, Metra M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrioventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J. 2008;29:1644-52.

465. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239-46.

466. Auricchio A, Metra M, Gasparini M, et al. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol. 2007;99:232-8.

467. Dong K, Shen WK, Powell BD, et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm. 2010;9:1240-5.

468. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76. doi:10.1016/j.jacc.2014.03.022.

469. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805-11.

470. Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2024;21(9):e31-e149. doi:10.1016/j.hrthm.2024.03.017.

471. Luigi DB, David C, Karl GH. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multicentre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017;19:132-8. doi:10.1093/europace/euw368.

472. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm. 2015;12:1162-8.

473. Sriram CS, Banchs JE, Moukabary T et al. Detection of left atrial thrombus byintracardiac echocardiography in patients undergoing ablation of atrial fibrillation. J Interv Card Electrophysiol, 2015;43(3):227-36. doi:10.1007/s10840-015-0008-2.

474. Lazoura O, Ismail TF, Pavitt C, et al. A low-dose, dual-phase cardiovascular CT protocol to assess left atrial appendage anatomy and exclude thrombus prior to left atrial intervention. Int J Cardiovasc Imaging. 2016;32:347-54.

475. Ren JF, Marchlinski FE, Callans DJ. Left atrial thrombus associated with ablation for atrial fibrillation: identification with intracardiac echocardiography. J Am Coll Cardiol. 2004;43:1861-7.

476. Saksena S, Sra J, Jordaens L, et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography inpatients with atrial fibrillation: the intracardiac echocardiography guided cardioversion helps interventional procedures study. Circ Arrhythm Electrophysiol. 2010;3:571-7.

477. Baran J, Stec S, Pilichowska-Paszkiet E, et al. Intracardiac echocardiography for detection of thrombus in the left atrial appendage: comparison with transesophageal echocardiography in patients undergoing ablation for atrial fibrillation: the Action-Ice I Study. Circ Arrhythm Electrophysiol. 2013;6:1074-81.

478. Ren JF, Marchlinski FE, Supple GE, et al. Intracardiac echocardiographic diagnosis of thrombus formation in the left atrial appendage: a complementary role to transesophageal echocardiography. Echocardiography. 2013;30:72-80.

479. Anter E, Silverstein J, Tschabrunn CM, et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages. Heart Rhythm, 2014;11:1890-7.

480. Zou H, Zhang Y, Tong J, Liu Z. Multidetector computed tomography for detecting left atrial/left atrial appendage thrombus: a meta-analysis. Intern Med J. 2015;35:1044-53.

481. Schmidt M, Segerson NM, Marschang H, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol. 2009;32:995-9.

482. Armbruster HL, Lindsley JP, Moranville MP, et al., Safety of novel oral anticoagulants compared with uninterrupted warfarin forcatheter ablation of atrial fibrillation. Ann Pharmacother. 2015;49:278-84.

483. Maleki K, Mohammadi R, Hart D, et al. Intracardiac ultrasound detection ofthrombus on transseptal sheath: incidence, treatment, and prevention. J Cardiovasc Electrophysiol. 2005;16:561-5.

484. Wazni OM, Rossillo A, Marrouche NF, et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol. 2005;16:576-81.

485. Shah D. Filamentous thrombi during left-sided sheath-assisted catheter ablations. Europace. 2010;12:1657-8.

486. Ren JF, Marchlinski FE, Callans DJ, et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures inpatients with spontaneous echo contrast. J Cardiovasc Electrophysiol. 2005;16:474-7.

487. Bruce CJ, Friedman PA, Narayan O, et al. Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. 2008;22:211-9.

488. Asbach S, Biermann J, Bode C, Faber TS. Early Heparin Administration Reduces Risk for Left Atrial Thrombus Formation during Atrial Fibrillation Ablation Procedures. Cardiol Res Pract. 2011;2011:615087.

489. Briceno DF, Villablanca PA, Lupercio F, et al. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression. J Cardiovasc Electrophysiol, 2016;27:683-93.

490. Chilukuri K, Henrikson CA, Dalal D, et al. Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation. J Interv Card Electrophysiol. 2009;25(3):175-81.

491. Calkins H1, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. 2012;33:171-257. doi:10.1007/s10840-012-9672-7.

492. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2007;4:816-61.

493. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018;20:157-208. doi:10.1093/europace/eux275.

494. Kleinecke C, Park JW, Gödde M, et al. Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J. 2017;24:131-8.

495. Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA. 2018;319:365-74.

496. Van Laar C, Verberkmoes NJ, van Es HW, et al. Thoracoscopic Left Atrial Appendage Clipping: A Multicenter Cohort Analysis. JACC Clin Electrophysiol. 2018;4:893-901.

497. Manolis AJ, Rosei EA, Coca A, et al. Hypertensionand atrial fibrillation: diagnostic approach, prevention and treatment. Position paperof the Working Group "Hypertension Arrhythmias and Thrombosis" of the European Society of Hypertension. J Hypertens. 2012;30:239-52.

498. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988-98.

499. Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-75.

500. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12.

501. Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75:3122-313.

502. Oliva A, Ioppolo AM, Chiarito M, et al. Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta‐ Analysis. J Am Heart Assoc. 2024;13:e034815.

503. Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14:1302-8.

504. Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143:1754-62.

505. Whitlock RP, Vincent J, Blackall MH, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol. 2013;29:1443-7.

506. Whitlock R, Healey J, Vincent J, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke (LAAOS) III. N Engl J Med. 2021;384:2081-91.

507. Martín Gutiérrez E, Castaño M, Gualis J, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280585 patients. Eur J Cardiothorac Surg. 2020;57:252-62. doi:10.1093/ejcts/ezz289.

508. Rashid HN, Layland J. Modification of the left atrial appendage and its role in stroke risk reduction with non-valvular atrial fibrillation. Int J Cardiol Heart Vasc. 2021;32:100688. doi:10.1016/j.ijcha.2020.100688.

509. Connolly SJ, Healey JS, Belley-Cote EP, et al. Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III. Circulation. 2023;148(17):1298-304. doi:10.1161/CIRCULATIONAHA.122.060315.

510. Madsen CL, Park-Hansen J, Irmukhamedov A, et al. LAACS-2 trial Investigators. The left atrial appendage closure by surgery-2 (LAACS-2) trial protocol rationale and design of a randomized multicenter trial investigating if left atrial appendage closure prevents stroke in patients undergoing open-heart surgery irrespective of preoperative atrial fibrillation status and stroke risk. Am Heart J. 2023;264:133-42. doi:10.1016/j.ahj.2023.06.003.

511. Sayed A, Kamal A, Kamal I, et al. Left Atrial Appendage Occlusion During Cardiac Surgery to Prevent Stroke: A Systematic Review and Meta-Analysis. Am J Cardiol. 2025;236:8-19. doi:10.1016/j.amjcard.2024.10.024.

512. Nso N, Nassar M, Zirkiyeva M, et al. Outcomes of cardiac surgery with left atrial appendage occlusion versus no occlusion, direct oral anticoagulants, and vitamin K antagonists: a systematic review with meta-analysis. Int J Cardiol Heart Vasc. 2022;40:100998. doi:10.1016/j.ijcha.2022.100998.

513. Park-Hansen J, Holme SJV, Irmukhamedov A, et al. Adding left atrial appendage closure to open heart surgery provides protection from ischemic brain injury six years after surgery independently of atrial fibrillation history: the LAACS randomized study. J Cardiothorac Surg. 2018;13:53. doi:10.1186/s13019-018-0740-7

514. Radakovic D, Penov K, Lazarus M, et al. The completeness of the left atrial appendage amputation during routine cardiac surgery. BMC Cardiovasc Disord. 2023;23(1):308. doi:10.1186/s12872-023-03330

515. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatmentand risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014;35:1205-14.

516. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintains in us rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-6.

517. Ueng K-C, Tsai T-P, Yu W-C, et al. Use of enalapril to facilitate sinus rhythm maintenance afterexternal cardioversion of long-standing persistent atrial fibrillation. Results of aprospective and controlled study. Eur Heart J. 2003;24:2090-8.

518. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9.

519. Anand K, Mooss AN, Hee TT, et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217-22.

520. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way ofabrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15:36-43.

521. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartanand various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544-8.

522. Antz M, Weiss C, Volkmer M, et al. Risk of suddendeath after successful accessory atrioventricular pathway ablation in resuscitatedpatients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol. 2002;13:231-6.

523. Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995;76:492-4.

524. Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologiccharacterization of accessory pathways on management strategies toreduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 1996;27:690-5.

525. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. European Society of Cardiology Committee, NASPE — Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias — executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed incollaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42:1493-531.

526. Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med. 2003;349:1803-11.

527. Boahene KA, Klein GJ, Yee R, et al. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol.1990;16:1408-14.

528. Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol. 1987;9:1357-63.

529. Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation. 1982;65:348-54.

530. Boriani G, Biffi M, Frabetti L, et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J. 1996;131:1214-6.

531. Schützenberger W, Leisch F, Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol. 1987;16:93-5.

532. Tijunelis MA, Herbert ME. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM. 2005;7:262-5.

533. Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol. 1984;54:330-5.

534. Vassiliadis I, Papoutsakis P, Kallikazaros I, Stefanadis C. Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. Int J Cardiol. 1990;27:63-70.

535. Feld GK, Nademanee K, Weiss J, et al. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol. 1984;3:1298-307.

536. Feld GK, Nademanee K, Stevenson W, et al. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Am Heart J. 1988;115:102-7.

537. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-24.

538. Elliott PM, Anastasakis A, Borge MA, et al. 2014 ESC Guidelines on diagnosisand management of hypertrophic cardiomyopathy: the Task Force forthe Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733-79.

539. Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83-99.

540. Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279-85.

541. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-240. doi:10.1016/j.jacc.2020.08.045.

542. Arbelo E, Protonotarios A, Gimeno JR, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-626. doi:10.1093/eurheartj/ehad194.

543. Spoladore R, Maron MS, D’Amato R, et al. Pharmacological Treatment Options for Hypertrophic Cardiomyopathy: High Time for Evidence. Eur Hear J. 2012;33(14):1724-33.

544. Patten M, Pecha S, Aydin A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation. 2018;10(5):1556.

545. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm. 2009;6:S51-5.

546. Kusunose K, Yamada H, Nishio S, et al. Clinical utility of single-beat E/e’ obtained by simultaneous recording off lowand tissue Doppler velocities in atrial fibrillation with preserved systolic function. JACC Cardiovasc Imaging. 2009;2:1147-56.

547. Li C, Zhang J, Zhou C, et al. Will simultaneous measurement of E/e’ index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-valvular atrial fibrillation? Eur J Echocardiogr. 2010;11(3):296-301. doi:10.1093/ejechocard/jep218.

548. Senechal M, O’Connor K, Deblois J, et al. A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in patients with atrial fibrillation. Echocardiography. 2008;25:57-63.

549. Sohn DW, Song JM, Zo JH, et al. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr. 1999;12:927-31.

550. Wada Y, Murata K, Tanaka T, et al. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J. 2012;76:675-81.

551. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient selection in heart failure with preservedejection fraction clinical trials. J Am Coll Cardiol. 2015;65:1668-82.

552. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021;42(48):4901. doi:10.1093/eurheartj/ehab670.

553. Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299-307.

554. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation inpatients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86-92.

555. Goette A, Schon N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5:43-51.

556. Disertori M, Latini R, Barlera S et al. GISSI-AF Investigators Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-17.

557. Yusuf S, Healey JS, Pogue J, et al. Active I Investigators Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928-38.

558. Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-43.

559. Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results fromthe EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598-603.

560. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997-2004.

561. Chiang CE, Naditch-Brule L, Murin J, et al. Distribution and risk profile ofparoxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the reallife global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632-39.

562. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-5.

563. Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke. 2014;45:520-6.

564. Schnabel RB, Yin X, Gona P. et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-62.

565. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98:946-52.

566. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-64.

567. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J. 2013;34:1061-7.

568. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:5260.

569. Hintze TD, Downing JV, Acquisto NM, et al. Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events. Am J Emerg Med. 2025;89:230-40. doi:10.1016/j.ajem.2024.12.070.

570. Andreotti F, Rocca B, Husted S, et al. ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert positionpaper of the European Society of Cardiology Working Group on Thrombosis.Eur Heart J. 2015;36:3238-49.

571. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e691S-736S.

572. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, et al. β-Blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med 2018;169:665-73. doi:10.7326/M18-0338.

573. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al.; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-241. doi:10.1093/eurheartj/ehy340.

574. Tsedenova EA. Pharmacotherapy of cardiac arrhythmias in pregnant women. Medical business. 2011;(4):18-29. (In Russ.) Цеденова Е. А. Фармакотерапия нарушений сердечного ритма у беременных. Лечебное дело. 2011;(4):18-29.

575. Chauveau S, Le Vavasseur O, Morel E, et al. Flecainide is a safe and effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle in pregnant women: a case series. Eur Heart J Case Rep. 2019;3(2):ytz066. doi:10.1093/ehjcr/ytz066.

576. Salam AM, Ertekin E, van Hagen IM, et al. Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol. 2015;1(4):284-92. doi:10.1016/j.jacep.2015.04.013.

577. Lee JCR, Wetzel G, Shannon K. Maternal arrhythmia management during pregnancy in patients with structural heart disease. Progress in Pediatric cardiology. 2004;19(1):71-82.

578. Aizer A, Gaziano JM, Cook NR, et al. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol. 2009;103:1572-7.

579. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidenceof atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118:800-7.

580. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than inthegeneral population? A systematic review and meta-analysis. Europace. 2009;11:1156-9.

581. Thelle DS, Selmer R, Gjesdal K, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309540 men and women. Heart. 2013;99:1755-60.

582. Andersen K, Farahmand B, Ahlbom A, et al. Risk of arrhythmias in 52755 long-distance cross-country skiers: a cohort study. Eur Heart J. 2013;34:3624-31.

583. Karjalainen J, Kujala UM, Kaprio J, et al. Lone atrial fibrillation invigorously exercising middle aged men: case-control study. BMJ. 1998;316:1784-5.

584. Calvo N, Mont L, Tamborero D, et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010;12:30-6.

585. Koopman P, Nuyens D, Garweg C, et al. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. Europace. 2011;13:1386-93.

586. Minaev AV, Mironenko MY, Dontsova VI, et al. Left Atrial Structural and Functional Changes in Adults with Congenital Septal Defects and Paroxysmal Atrial Fibrillation. J Clin Med. 2024;13(19):6023. doi:10.3390/jcm13196023.

587. Бабаева А. Н., Подзолков В. П., Чиаурели М. Р. и др. Особенности и результаты коррекции врожденных пороков сердца у пожилых пациентов. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2024;25(S3):6. EDN: KTXFOL.

588. Yamada T, McElderry HT, Muto M, et al. Pulmonary vein isolationin patients with paroxysmal atrial fibrillation after direct suture closure of congenitalatrial septal defect. Circ J. 2007;71:1989-92.

589. Минаев А. В., Сергуладзе С. Ю., Мироненко М. Ю. и др. Фибрилляция предсердий при врожденных пороках сердца: предикторы развития, тактика лечения и результаты хирургии. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2024;25(S6):10. EDN: WFUODA.

590. Shim H, Yang JH, Park PW, et al. Efficacy of the maze procedure foratrial fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg. 2013;46:98-103.

591. Gutierrez SD, Earing MG, Singh AK, et al. Atrial tachyarrhythmiasand the Coxmaze procedure in congenital heart disease. Congenit Heart Dis. 2013;8:434-9.

592. Bockeria L, Golukhova E, Dadasheva M, et al. Advantages and disadvantages of one-stage and two-stage surgery for arrhythmias and Ebstein’s anomaly. Eur J Cardiothorac Surg. 2005;28:536-40.

593. Бокерия Л. А., Ревишвили А. Ш., Шмуль А. В. и др. Результаты хирургического лечения фибрилляции предсердий у пациентов с пороками сердца. Анналы аритмологии. 2012;(4):14-22.

594. Jensen AS, Idorn L, Norager B, et al. Anticoagulation in adult swith congenital heart disease: The who, the when and the how? Heart. 2014;101:424-42.

595. Ammash NM, Phillips SD, Hodge DO, et al. Outcome of direct current cardioversion for atrial arrhythmiasin adults with congenital heart disease. Int J Cardiol. 2012;154:270-4.

596. Feltes TF, Friedman RA. Transesophageal echocardiographic detection ofatrialthrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol. 1994;24:1365-70.

597. Goldstone AB, Patrick WL, Cohen JE, et al. Early surgical intervention or watchful waiting for the management of asymptomatic mitral regurgitation: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2015;4:220-9.

598. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk ofincident atrial fibrillation in women. J Am Coll Cardiol. 2012;60:1421-8.

599. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascularevents and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30:1128-35.

600. Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodesof atrial fibrillation in type 2 diabetes. J Diabetes Complications. 2015;29:88-92.

601. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.

602. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation anddiabetes. J Cardiovasc Electrophysiol. 2015;26:223-5.

603. Overvad TF, Skjoth F, Lip GY, et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke. 2015;46:2168-74.

604. Bitter T, Nolker G, Vogt J, et al. Predictors of recurrencein patients undergoing cryoballoon ablation for treatment of atrial fibrillation: the independent role of sleep-disordered breathing. J Cardiovasc Electrophysiol. 2012;23:18-25.

605. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructivesleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108:47-51.

606. Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a different sort. Am J Cardiol. 2012;110:1071.

607. Patel D, Mohanty P, Di Biase L, et al. Safety andefficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol. 2010;3:445-51.

608. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation followingradiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm. 2013;10:331-7.

609. Neilan TG, Farhad H, Dodson JA, et al. Effect of sleep apnea and continuous positive airway pressure on cardiacstructure and recurrence of atrial fibrillation. J Am Heart Assoc. 2013;2:e000421.

610. Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. Indian Heart J. 2017;69(4):545-50. doi:10.1016/j.ihj.2017.07.004.

611. Vaidya B, Pearce SHS. Diagnosis and management of thyrotoxicosis. BMJ. 2014;349:g5128. doi:10.1136/bmj.g5128.

612. Benjamin AS, Sunghee K, Jonathan PP, et al. Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721-8.

613. Бойцов С.А., Лукьянов М. М., Якушин С. С. и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50. doi:10.15829/1728-8800-2014-6-3-8.

614. Bansal N, Zelnick LR, Alonso A, et al. eGFR and albuminuria in relation to risk of incident atrial fibrillation: ameta-analysis of the Jackson Heart Study, theMulti-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12:1386-98.

615. Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135:e146-e603.

616. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney diseases. N Engl J Med. 2012;367:625-35.

617. Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007;53:766-72.

618. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.

619. Risom SS, Zwisler AD, Johansen PP, et al. Exercise-based cardiac rehabilitation for adults with atrial fibrillation. Cochrane Database of Systematic Reviews. 2016;5:CD011197.

620. Shi S, Shi J, Jia Q, et al. Efficacy of Physical Exercise on the Quality of Life, Exercise Ability, and Cardiopulmonary Fitness of Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Physiol. 2020;11:740. doi:10.3389/fphys.2020.00740.

621. Ortega-Moral A, Valle-Sahagún B, Barón-Esquivias G. Efficacy of exercise in patients with atrial fibrillation: Systematic review and meta-analysis. Med Clin (Barc). 2022;159(8):372-9. English, Spanish. doi:10.1016/j.medcli.2021.11.013

622. Robaye B, Lakiss N, Dumont F, Laruelle C. Atrial fibrillation and cardiac rehabilitation: an overview. Acta Cardiol. 2020;75(2):116-20. doi:10.1080/00015385.2019.1565663.

623. Bittman J, Thomson CJ, Lyall LA, et al. Effect of an Exercise and Nutrition Program on Quality of Life in Patients With Atrial Fibrillation: The Atrial Fibrillation Lifestyle Project (ALP). CJC Open. 2022;4(8):685-94. doi:10.1016/j.cjco.2022.04.004.

624. Kato M, Kubo A, Nihei F, et al. Effects of exercise training on exercise capacity, cardiac function, BMI, and quality of life in patients with atrial fibrillation: a meta-analysis of randomized-controlled trials. Int J Rehabil Res. 2017;40:193-201.

625. Smart NA, King N, Lambert JD, et al. Exercise-based cardiac rehabilitation improves exercise capacity and health-related quality of life in people with atrial fibrillation: a systematic review and meta-analysis of randomised and non-randomised trials. Open Heart. 2018;5:e000880.

626. Wahlstrom M, Rydell Karlsson M, Medin J, et al. Effects of yoga in patients with paroxysmal atrial fibrillation — a randomized controlled study. Eur J Cardiovasc Nurs. 2017;16:57-63.

627. Skielboe AK, Bandholm TQ, Hakmann S, et al. Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation — A randomized controlled trial. PLoS One. 2017;12:e0170060.

628. Lowres N, Neubeck L, Freedman SB, et al. Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. European Journal of Preventive Cardiology. 2011;19:1091-100.

629. Mandic S, Tymchak W, Kim D, et al. Effects of aerobic or aerobic and resistance training on cardiorespiratory and skeletal muscle function in heart failure: a randomized controlled pilot trial. Clin. Rehabil. 2009;23:207-16.

630. Mohanty S, Mohanty P, Tamaki M, et al. Differential association of exercise intensity with risk of atrial fibrillation in men and women: Evidence from a meta-analysis. J. Cardiovasc. Electrophysiol. 2016;27:1021-9. doi:10.1111/jce.13023.

631. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in olderadults: recommendation from the American college of sports medicine and the American heart association. Med. Sci. Sports Exerc. 2007;39:1435-45. doi:10.1249/mss.0b013e3180616aa2.

632. De Maeyer C, Beckers P, Vrints CJ, Conraads V. M. Exercisetraining in chronic heart failure. Ther. Adv. Chronic Dis. 2013;4:105-17. doi:10.1177/2040622313480382.

633. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation European Heart Journal. 2012;33:2692-9.

634. Zhang Y, Ren P, Tang A, et al. Efficacy of Exercise Rehabilitation in Patients with Atrial Fibrillation after Radiofrequency Ablation: A Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2022;2022:9714252. doi:10.1155/2022/9714252.

635. Risom SS, Zwisler AD, Sibilitz KL, et al. Cardiac Rehabilitation for Patients Treated for Atrial Fibrillation With Ablation Has Long-Term Effects: 12-and 24-Month Follow-up Results From the Randomized CopenHeartRFA Trial. Arch Phys Med Rehabil. 2020;101(11):1877-86. doi:10.1016/j.apmr.2020.06.026.

636. Kato M, Ogano M, Mori Y, et al. Exercise-based cardiac rehabilitation for patients with catheter ablation for persistent atrial fibrillation: A randomized controlled clinical trial. Eur J Prev Cardiol. 2019;26(18):1931-40. doi:10.1177/2047487319859974.

637. Malmo V, Nes BM, Amundsen BH, et al. Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial. Circulation. 2016;133(5):466-73. doi:10.1161/CIRCULATIONAHA.115.018220.

638. Бубнова М. Г., Аронов Д. М., Махинова М. М., Давтян К. В. Клиническая эффективность персонализированной программы физических тренировок в реабилитации пациентов с фибрилляцией предсердий после операции радиочастотной аблации. Российский кардиологический журнал. 2022;27(7):5098. doi:10.15829/1560-4071-2022-5098

639. Stewart S, Ball J, Horowitz JD, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385:775-84.

640. An J, Niu F, Zheng C, et al. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017;23:700-12.

641. Visseren FLJ, Mach F, Smulders YM, et al. ESC Scientific Document Group, 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022;43(42):4468. doi:10.1093/eurheartj/ehac458.

642. Overvad TF, Rasmussen LH, Skjoth F, et al. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013;99:1093-9.

643. Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:1233-45.

644. Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk incpatients with non-valvular atrial fibrillation: a systematic review. ThrombcHaemost. 2018;118:2171-87.

645. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26:331-42.

646. Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on nonvitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209-18.

647. Aliot E, Breithardt G, Brugada J, et al. Atrial Fibrillation AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart Federation (WHF)]. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626-33.

648. Hohnloser SH, Crijns H, Jvan Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-78.

649. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76

650. Schmidt-Lucke C, Paar WD, Stellbrink C, et al. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res. 2007;119(1):27-34. doi:10.1016/j.thromres.2005.11.016.

651. Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med. 2013;20(3):222-30. doi:10.1111/acem.12091.

652. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989;13(1):1-6. doi:10.1097/00005344-198901000-00002.

653. Channer KS, James MA, MacConnell T, Rees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol. 1994;37(1):53-7. doi:10.1111/j.1365-2125.1994.tb04238.x.

654. Khand AU, Rankin AC, Martin W, et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944-51. doi:10.1016/j.jacc.2003.07.020.

655. Ulimoen SR, Enger S, Carlson J, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225-30. doi:10.1016/j.amjcard.2012.09.020.

656. Шубик Ю. В., Медведев М. М., Крятова Т. В. Контроль частоты сердечных сокращений у больных с тахисистолической фибрилляцией предсердий с помощью небиволола. Кардиология. 2003;43(9):52-5.

657. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 1988;9(7):777-81. doi:10.1093/eurheartj/9.7.777.

658. Dahlström CG, Edvardsson N, Nasheng C, Olsson SB. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. Clin Cardiol. 1992;15(4):280-4. doi:10.1002/clc.4960150411.

659. Tamargo J, Capucci A, Mabo P. Safety of flecainide. Drug Saf. 2012;35(4):273-89. doi:10.2165/11599950-000000000-00000.

660. Sulzgruber P, Wassmann S, Semb AG, et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J Cardiovasc Pharmacother. 2019;5(3):171-80.